• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Fractyl Health

Fractyl Health

Transformative Metabolic Therapies

  • Investors
  • Clinical Studies
  • Careers
  • Our Focus
    • Obesity
    • Type 2 Diabetes
  • Our Platforms
    • Revita
    • Rejuva
  • Our Science
    • Clinical Studies
    • Presentations & Publications
  • Our Company
    • Culture
    • Our Team
    • Careers
  • Our News
    • Media Kit
Home/Presentation

Single-Dose GLP-1-Based Pancreatic Gene Therapy Durably Maintains Body Composition and Glycemia After Semaglutide Withdrawal in a Murine Model of Obesity

Presentation

June 23, 2024 by

May 20, 2024 by

May 13, 2024 by

December 28, 2023 by

October 28, 2023 by

June 29, 2023 by

June 28, 2023 by

May 30, 2023 by

May 29, 2023 by

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Interim pages omitted …
  • Page 8
  • Go to Next Page »

Footer

LinkedIn X, formally Twitter Facebook
© 2014-2024 Fractyl Health, Inc. All Rights Reserved.
  • Contact
  • Privacy & Cookie Policy
  • Terms of Use
  • Intellectual Property
  • Transparency in Coverage
logo
  • Our Focus
    • Obesity
    • Type 2 Diabetes
  • Our Platforms
    • Revita
    • Rejuva
  • Our Science
    • Clinical Studies
    • Presentations & Publications
  • Our Company
    • Culture
    • Our Team
    • Careers
  • Our News
    • Media Kit
  • Investors